- $76.59m
- $20.06m
- €8.28m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.23 | ||
| Price to Tang. Book | 1.24 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.63 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -149.7% | ||
| Return on Equity | -100.55% | ||
| Operating Margin | -1288.95% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 21.39 | 28.36 | 40.37 | 41.35 | 8.28 | 5.29 | 6.15 | -19% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Directors
- Thomas Hecht CSU (70)
- Adi Hoess CEO (59)
- Angus Smith CFO (38)
- Wolfgang Fischer COO (57)
- Arndt Schottelius CSO (54)
- Andreas Harstrick MGB (59)
- Denise Mueller MGB
- Bernhard Ehmer IND (66)
- Ulrich Grau IND (72)
- Mathieu Simon IND (64)
- Ferdinand Verdonck IND (78)
- Annalisa Jenkins SUB (55)
- Uta Kemmerich-Keil SUB (55)
- Harry Welten SUB (55)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 28th, 2014
- Public Since
- September 12th, 2014
- No. of Shareholders
- 8
- No. of Employees
- 76
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 15,227,463
- Address
- Gottlieb-Daimler-Strasse 2, MANNHEIM, 68165
- Web
- https://www.affimed.com/
- Phone
- +49 621560030
- Contact
- Alexander Fudukidis
- Auditors
- KPMG AG Wirtschaftsprufungsgesellschaft
Upcoming Events for AFMD
Affimed NV Annual Shareholders Meeting
Q2 2024 Affimed NV Earnings Release
Similar to AFMD
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Affimed NV share price?
As of Today at 19:00 UTC, shares in Affimed NV are trading at $5.03. This share price information is delayed by 15 minutes.
How has the Affimed NV share price performed this year?
Shares in Affimed NV last closed at $5.03 and the price had moved by -44.11% over the past 365 days. In terms of relative price strength the Affimed NV share price has underperformed the S&P500 Index by -54.31% over the past year.
What are the analyst and broker recommendations for Affimed NV?
The overall consensus recommendation for Affimed NV is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Affimed NV dividend yield?
Affimed NV does not currently pay a dividend.
Does Affimed NV pay a dividend?
Affimed NV does not currently pay a dividend.
When does Affimed NV next pay dividends?
Affimed NV does not currently pay a dividend.
How do I buy Affimed NV shares?
To buy shares in Affimed NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Affimed NV?
As of the previous close price of $5.03, shares in Affimed NV had a market capitalisation of $76.59m.
Where are Affimed NV shares listed?
Here are the trading details for Affimed NV:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: AFMD
What kind of share is Affimed NV?
Based on an overall assessment of its quality, value and momentum Affimed NV is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Affimed NV share price forecast for 2024?
The analyst consensus target price for shares in Affimed NV is $22.56. That is 348.57% above the last closing price of $5.03.
Analysts covering Affimed NV currently have a consensus Earnings Per Share (EPS) forecast of -€4.90 for the next financial year.
What is the trend in the Affimed NV share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Affimed NV. Over the past six months, its share price has outperformed the S&P500 Index by +29.52%.
As of the last closing price of $5.03, shares in Affimed NV were trading -2.19% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Affimed NV PE Ratio?
The Affimed NV PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Affimed NV?
Affimed NV's management team is headed by:
- Thomas Hecht - CSU
- Adi Hoess - CEO
- Angus Smith - CFO
- Wolfgang Fischer - COO
- Arndt Schottelius - CSO
- Andreas Harstrick - MGB
- Denise Mueller - MGB
- Bernhard Ehmer - IND
- Ulrich Grau - IND
- Mathieu Simon - IND
- Ferdinand Verdonck - IND
- Annalisa Jenkins - SUB
- Uta Kemmerich-Keil - SUB
- Harry Welten - SUB